A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression

Bibliographic Data

ID15525225
AuthorsJohannes T Reckweg (0000-0001-7916-6334, Maastricht University, corresponding author), C J Van Leeuwen (0000-0003-1605-4268, Maastricht University), Cécile Henquet (0000-0002-7051-5945, Maastricht University), Thérèse van Amelsvoort (0000-0003-1135-5133, Maastricht University), Eef L Theunissen (0000-0002-6071-1758, Maastricht University), Natasha L Mason (0000-0001-7115-0389, Maastricht University), Riccardo Paci (Maastricht University), Theis H Terwey, Johannes G Ramaekers (0000-0003-4553-376X, Maastricht University, corresponding author)
Year2023
Volume14
Pages1133414-1133414
Publication date2023-06-20
Open AccessYes
TypeARTICLE
VenueFrontiers in Psychiatry (JOURNAL)
Journal identifiersISSN: 1664-0640 • E-ISSN: 1664-0640
PublisherFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2023.1133414
PMID37409159
OpenAlexW4381433809
LanguageEN
Citations received4
References cited32

Administration of GH001 to a cohort of 16 patients with TRD was well tolerated and provided potent and ultra-rapid antidepressant effects. Individualized dosing with up to three doses of GH001 on a single day was superior to single dose administration. Clinical Trial registration : Clinicaltrials.gov Identifier NCT04698603

Adverse effect · Antidepressant · Clinical endpoint · Clinical trial · Depression (economics · Dosing · Regimen · Treatment-resistant depression · Chemical synthesis and alkaloids · Medicine · Neurotransmitter Receptor Influence on Behavior · Psychedelics and Drug Studies · Internal Medicine · Pharmacology

Tools

Open DOIOpen Access